Fig. 7From: Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysisForest plots for predictive analyses of EGFR ligands in trials comparing experimental arm with control arm—a progression-free survival, b overall survival and c objective response rate. NA, not available; PFS, progression-free survival; OS overall survival; ORR, objective response rateBack to article page